ICON PLC (ICLR) stock
Close on Nov 11, 2026Market cap $15.29BP/E 34.4Yield –
ICON PLC grew revenue 0.4% to $8.23B over the twelve months to Sep 30, 2026. Operating income rose 27.0% to $718.25M, moving the operating margin from 6.9% to 8.7%. Free cash flow was $857.06M, down 11.1% from a year earlier. At the latest close the market valued the company at $15.29B, 34.4 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $15.29B
- P/E ratio
- 34.4
- Price to sales
- 1.86
- Price to book
- 1.68
- Dividend yield
- –
- Free cash flow yield
- 5.61%
Fundamentals
- Revenue
- $8.23B
- Net income
- $448.66M
- EPS, diluted
- $5.81
- Free cash flow
- $857.06M
- Book value per share
- $117.92
- Diluted shares
- 77M
Trading
- Previous close
- $204.63
- Open
- $204.32
- Day's range
- $199.41 – $208.38
- Volume
- 647,315
- Average volume (20 days)
- 1,245,927
- Beta (5 years)
- 1.21
- 52-week range
- $66.57 – $219.04
- RSI (14 days)
- 58.1
- Volatility (1 year)
- 68.4%
- Relative volume
- 0.71×
- WACC
- 9.9%
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ICLR | S&P 500 | Difference | ICLR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +21.6% | -2.4% | +24.1 pts | ||
| 3 months | +20.6% | -1.2% | +21.8 pts | ||
| Year to date | +9.6% | +12.3% | −2.7 pts | ||
| 1 year | +22.2% | +12.4% | +9.8 pts | ||
| 3 years | -22.1% | +78.8% | −100.9 pts | -8.0% | +21.4% |
| 5 years | -27.4% | +75.2% | −102.6 pts | -6.2% | +11.9% |
| 10 years | +149.0% | +311.1% | −162.1 pts | +9.6% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases ICON filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About ICON
Services-Commercial Physical & Biological Research
ICON public limited company is a contract research organization that provides outsourced development, commercialization, and consulting services to the pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company supports all phases of the clinical development process, from compound selection through Phase I to IV clinical studies, post-approval research, and market access. Its core service offerings encompass clinical development, functional service partnerships, decentralized clinical trial solutions, and specialized laboratory testing, including bio-analytical, biomarker, vaccine, and central laboratory services.
Company profile, executives and historyICON stock: common questions
What is ICON's stock price?
ICLR closed at $199.70 on Nov 11, 2026, down 2.41% on the day. Over the past 52 weeks it traded between $66.57 and $219.04.
What is ICON's market cap?
ICON was worth $15.29B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ICLR's P/E ratio?
ICLR trades at 34.4 times earnings, based on diluted earnings per share of $5.81 over the twelve months to Sep 30, 2026.
How much revenue does ICON make?
ICON reported revenue of $8.23B for the twelve months to Sep 30, 2026, up 0.4% from a year earlier.
Does ICON pay a dividend?
No. ICON has not paid a cash dividend over the last twelve months.
How has ICLR stock performed over the past year?
Including dividends, ICLR returned +22.2% over the past year, against +12.4% for the S&P 500.
How many ICLR shares are sold short?
2M shares were sold short at the latest FINRA report, 3.12% of the float, or 1.7 days of average trading volume.
Who are ICON's competitors?
Companies most similar to ICON by business, industry and size include IQV, MEDP, CRL, INCY, FTRE.
See a number that looks wrong?